Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Key House committee advances nationwide voter ID bill,...
FDA refuses to review Moderna’s mRNA flu vaccine...
Trump, Netanyahu to meet at White House in...
Vance warns Iran that ‘another option on the...
Meta, Google face massive liability as ‘addicted kids’...
Trump to host ‘Clean Beautiful Coal’ event, calls...
Russia agrees to abide by expired New START...
Israel joins Board of Peace ahead of Netanyahu-Trump...
Bondi confirms DOJ has received criminal referral alleging...
Schumer, Dems choose partial shutdown as negotiations hit...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Teenage cancer patient’s final fight becomes law as House passes landmark pediatric bill

by admin December 6, 2025
December 6, 2025
Teenage cancer patient’s final fight becomes law as House passes landmark pediatric bill

A teenage girl who spent her final years advocating for young people battling cancer is forever memorialized in history, thanks to a key bill passed by the House of Representatives.

Mikaela Naylon was just 16 when she died five years after being diagnosed with osteosarcoma, a rare form of bone cancer.

Rep. Michael McCaul, R-Texas, who helped lead the landmark legislation that became her namesake, said Mikaela spent much of that time fighting to give fellow children a chance to survive cancer.

He told Fox News Digital that he viewed childhood cancer patients as ‘the best advocates’ for their cause, calling them his ‘better angels.’

‘Mikaela was a great example of that,’ McCaul said. ‘She was very sick. She’d just undergone radiation and chemotherapy. She wasn’t feeling very well, and I could tell. But she still made the effort to come to Washington, to go to members’ offices and advocate for the legislation.’

The Mikaela Naylon Give Kids A Chance Act is aimed at expanding children’s access to existing cancer therapy trials, as well as incentivizing development of treatments and solutions for pediatric cancer.

It reauthorizes funding for the National Institutes of Health (NIH) to support pediatric disease research through fiscal year 2027, and extends the Food and Drug Administration’s (FDA) ability to expedite review of drugs aimed at helping certain pediatric illnesses.

‘It’s probably one of the most rewarding things I’ve done is to not only draw awareness to childhood cancer by forming the [Childhood Cancer Caucus] and then having an annual summit, but to be able to pass legislation that results in saving children’s lives. I don’t think there’s anything more important than that,’ McCaul said.

His bill passed the House unanimously on Monday, with both Republicans and Democrats speaking out in strong support for the legislation.

Mikaela’s family was in attendance to watch both its passage and the speeches lawmakers gave in favor of it.

‘Nothing will take the place of her. But it helped fill kind of a void, an emptiness they have right now. And they’re very proud of that, that her legacy is carried on through this legislation,’ McCaul, who also gave the Naylon family a tour of the U.S. Capitol, said.

Mikaela’s parents Kassandra and Doug, and her brother Ayden, told Fox News Digital that she had ‘faced every day with hope, purpose and a fierce determination to make the world better for the kids who would come after her.’

‘She believed that all children, no matter how rare their diagnosis, deserve access to the most promising treatments and a real chance at life. This legislation reflects that mission,’ the Naylon family told Fox News Digital.

They thanked McCaul as well as Reps. Debbie Dingell, D-Mich., and Gus Bilirakis, R-Fla., for championing the bill, as well as advocacy groups who also helped shepherd it forward.

‘Their commitment ensures that Mikaela‘s voice, and the voices of so many brave children like her, will forever be heard in the halls of Congress,’ the family said.

This post appeared first on FOX NEWS

previous post
State-level AI rules survive — for now — as Senate sinks moratorium despite White House pressure
next post
Trump signs off on nationwide vaccine schedule review as CDC withdraws infant hep B guidance: ‘Fast track’

You may also like

Reagan-appointed judge, once rebuked by Supreme Court, continues...

October 3, 2025

Fetterman calls out Dems’ flip: ‘We ran on...

October 21, 2025

‘Most damning evidence’: Hunter Biden’s full pardon resurfaces...

December 6, 2024

What’s next for Iran’s terror army, the IRGC,...

July 2, 2025

Trump warns ‘sick’ South American leader, reiterates ‘we...

January 5, 2026

Trump announces two-year closure of Trump Kennedy Center...

February 2, 2026

Russia launches largest attack on Ukraine this month...

August 20, 2025

Biden’s stunning exit, one year later: The dropout...

July 21, 2025

Trump official blasts Washington Post for ‘fake news’...

February 28, 2025

Pastor Max Lucado: Surviving a challenging election season...

August 11, 2024

Recent Posts

  • Key House committee advances nationwide voter ID bill, setting up 2026 election fight
  • FDA refuses to review Moderna’s mRNA flu vaccine application
  • Trump, Netanyahu to meet at White House in high-stakes talks on Iran, Gaza plan
  • Vance warns Iran that ‘another option on the table’ if nuclear deal not reached
  • Meta, Google face massive liability as ‘addicted kids’ trial continues in LA

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (973)
    • Investing (4,091)
    • Politics (4,927)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 Sightful Invest. All Rights Reserved.